CYP46A1 and Dravet syndrome: However, soticlestat, an inhibitor of cholesterol 24-hydroxylase that reduces inflammatory markers, failed to meet primary clinical endpoints for seizure reduction in Dravet syndrome and Lennox–Gastaut syndrome [102], despite favorable results in a mouse model of Dravet syndrome [103].